IIPR is using its IQHQ investment to diversify beyond its cannabis-heavy real estate portfolio into life-science properties; life sciences represented 12.2% of base rent and interest as of June 30, 2026, while its IQHQ investment had reached $270 million. Alewife Park is a 762,000-square-foot life-science campus in development, anchored by Lila Sciences’ 244,000-square-foot lease.
The financing materially advances the Alewife project, but it is primarily a refinancing-and-funding package rather than fresh growth capital. The amendment increases the mezzanine loan by up to $267 million, with $245 million in Note B and $22 million in Note C. A portion must immediately repay the existing $85 million bridge loan and release its liens, while the remaining proceeds can fund tenant improvements, landlord work, campus amenities, reserves, extension fees and closing costs.
| Filing item | Amount / term |
|---|---|
| Existing mezzanine Note A | $133 million |
| Loan increase — Note B | $245 million |
| Loan increase — Note C | $22 million |
| Total loan increase | $267 million |
| Bridge loan to be repaid | $85 million |
| Minimum applicable rate | 14% per annum |
| Origination fee | 0.50% of increase |
| Underwriting fee | 0.50% of increase |
| Exit fee | 1.0% of amount repaid |
| Required conversion completion | December 31, 2026 |
| Second-extension debt-yield threshold | 6.75% |
The key trade-off is costly leverage for project continuity. The loan carries a minimum 14% rate, plus origination and underwriting fees, and the structure can impose additional interest if the lender’s minimum-return amount is not met. That makes the financing supportive of the buildout operationally, but expensive for IIPR and more dependent on the property reaching stabilization and generating sufficient income.
The amendment also tightens execution risk around the development. IIPR receives an extension of the initial maturity date and retains a potential second extension, but the borrower must complete the conversion component by December 31, 2026 or face an event of default. The second extension is also made more permissive on leverage, with the maximum aggregate as-is loan-to-value ratio raised to 75%, but it requires a 6.75% debt yield or a prepayment, letter of credit or additional collateral.
The right-of-first-offer provision gives the Note B lender an added claim on the asset’s future financing or sale. Once Note B funding reaches $155 million, that lender or an affiliate can take priority over the broader lender group’s right to negotiate a purchase, financing or refinancing of the property. This does not change the current operating business, but it reduces flexibility around a future disposition or recapitalization.
Bottom line: The amendment keeps the Alewife Park life-science strategy funded and replaces bridge debt with a larger, longer-term facility. It advances the project, but the high-cost capital and hard completion milestones make execution—not financing availability—the more important next test.
Read the original 8-K on SEC EDGAR ↗